Author: admin

Introduction: When Common Conditions Become Systemic Burdens Erectile dysfunction (ED) and benign prostatic hyperplasia-associated lower urinary tract symptoms (BPH-LUTS) are among the most prevalent chronic conditions affecting aging men. Individually, each condition carries a measurable burden. Together, they create a…

Introduction: When One Symptom Demands More Than One Solution Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) are rarely life-threatening—but they are persistently life-altering. Patients describe not just difficulty urinating, but disrupted sleep, reduced confidence, and a…

Introduction: When the Patient Becomes the Outcome Erectile dysfunction (ED) is one of the few medical conditions where success cannot be measured by laboratory values, imaging, or biomarkers. It is, fundamentally, a subjective experience. Either the patient is satisfied—or he…

Introduction: When Evidence Meets Cultural Reality Erectile dysfunction (ED) is often described in universal physiological terms, yet its clinical expression is deeply shaped by cultural, psychological, and social factors. Nowhere is this more evident than in East and Southeast Asia,…

Introduction: When One Disease Becomes Two Problems Benign prostatic hyperplasia (BPH) is often presented as a simple anatomical issue—an enlarged prostate obstructing urinary flow. In reality, it is a far more complex and multifaceted condition. For the aging male patient,…

Introduction: From Erectile Function to Reproductive Potential Tadalafil has long occupied a well-defined role in clinical medicine—as a reliable and effective treatment for erectile dysfunction. Its pharmacological identity is clear: a phosphodiesterase type 5 (PDE5) inhibitor that enhances nitric oxide–mediated…

Introduction: When Timing Becomes Therapy Erectile dysfunction (ED) is often discussed in terms of physiology, vascular health, and pharmacology. Yet in clinical reality, it is just as much about timing, spontaneity, and personal preference. The success of any therapy depends…

Introduction: A 21st-Century Disease with 18th-Century Roots Pulmonary hypertension (PH) is a diagnosis that commands urgency. It evokes images of progressive vascular remodeling, right heart failure, and complex, often lifelong therapy. Clinicians are trained to think in terms of idiopathic…

Introduction: The Hidden Cost of Surgical Cure Radical prostatectomy remains one of the most effective curative treatments for localized prostate cancer. It is a procedure that removes disease with precision—but often leaves behind a different kind of burden. For many…

Introduction: Precision Medicine Demands Precision Analytics In contemporary oncology, the therapeutic strategy rarely relies on a single drug. Instead, it often involves carefully coordinated pharmacological combinations designed to maximize efficacy while mitigating adverse effects. This is particularly evident in breast…

Introduction: When Molecular Biology Meets Global Health Parasitic nematode infections remain one of the most underestimated burdens in global medicine. Affecting up to billions of people worldwide, these infections are not merely inconvenient—they impair growth, cognition, and economic productivity on…

Introduction: When a Rare Case Redefines a Familiar Condition Priapism is a term that most clinicians associate with human urology, occasionally encountered, rarely welcomed, and always urgent. Defined as a prolonged erection unrelated to sexual stimulation, it represents a failure…

Introduction: A Familiar Drug in an Unexpected Role Chronic kidney disease (CKD) remains one of the most pressing challenges in global health. Its progression is often silent, relentless, and tightly interwoven with other chronic conditions such as hypertension, diabetes, and…

Introduction: A Drug Meets a Metabolic Reality Tadalafil is widely recognized as a cornerstone therapy in erectile dysfunction, valued for its prolonged duration of action and favorable pharmacokinetic profile. Unlike its shorter-acting counterparts, it offers a window of therapeutic flexibility…

Introduction: When a Vascular Drug Reaches the Inner Ear Phosphodiesterase type 5 inhibitors (PDE5 inhibitors) have long secured their place in clinical practice. Originally developed as vasodilators, they are now widely prescribed for erectile dysfunction, pulmonary hypertension, and even selected…

Introduction: A Familiar Drug Class Enters Unfamiliar Territory Modern neurology faces a paradox. Despite decades of research, Alzheimer’s disease and related dementias (ADRD) remain only partially understood and poorly treated. The therapeutic arsenal is limited, often focused on symptomatic relief…

Introduction: A Disease at the Intersection of Hematology and Cardiology Pulmonary hypertension (PH) associated with myeloproliferative neoplasms (MPNs) occupies a uniquely complex space in modern medicine. It is neither purely vascular nor exclusively hematologic; instead, it represents a convergence of…

Introduction: When Therapy Becomes Lifestyle Phosphodiesterase type 5 inhibitors (PDE5 inhibitors) have transformed the management of erectile dysfunction (ED), offering an effective, well-tolerated, and convenient oral therapy. Drugs such as sildenafil, vardenafil, and tadalafil have become synonymous with modern sexual…

Introduction: When Efficacy Meets Experience Pulmonary arterial hypertension (PAH) has undergone a therapeutic transformation over the past two decades. Once a relentlessly progressive and fatal disease, it is now managed through targeted pharmacological strategies that significantly improve survival and quality…

Introduction: From Needles to Photons in Erectile Research Erectile function has long been a subject of both clinical importance and scientific curiosity. While pharmacological breakthroughs—most notably phosphodiesterase type-5 inhibitors such as tadalafil—have transformed treatment, understanding the underlying physiology still relies…

Introduction: From Vascular Drug to Renal Modulator Tadalafil has long been associated with vascular medicine—most notably erectile dysfunction and pulmonary arterial hypertension. Its mechanism, centered on enhancing nitric oxide (NO)–mediated signaling, has been thoroughly studied in the context of smooth…

Introduction: A Condition Defined by Seconds, Experienced in Years Premature ejaculation (PE) is one of the most common male sexual disorders, yet also one of the least consistently understood. For many patients, it is not simply a matter of reduced…

Introduction: When a Familiar Drug Enters Unfamiliar Territory In clinical medicine, certain drugs become so closely associated with a single indication that their broader potential is often overlooked. Tadalafil, a well-established phosphodiesterase type-5 (PDE5) inhibitor, is one such example. Known…

Introduction: When Pharmacology Meets Formulation Science Tadalafil has established itself as one of the most effective and widely used phosphodiesterase type-5 (PDE5) inhibitors in modern medicine. Its long half-life, predictable pharmacokinetics, and clinical versatility make it a preferred option for…

Introduction: The Limits of Success in Modern PAH Therapy Pulmonary arterial hypertension (PAH) is no longer the uniformly fatal diagnosis it once was. Advances in targeted therapies have transformed the disease into a chronic, manageable condition for many patients. Among…

Introduction: When “Herbal” Is Not What It Seems The global market for sexual enhancement products has expanded dramatically over the past two decades. Dietary supplements, herbal mixtures, and traditional medicines are widely marketed as “natural” alternatives to prescription drugs for…

Introduction: Beyond Symptom Relief in Erectile Dysfunction Erectile dysfunction (ED) in patients with diabetes mellitus is not merely a functional inconvenience—it is a complex vascular and metabolic disorder rooted in oxidative stress, endothelial dysfunction, and structural damage to penile tissue….

Introduction: Rethinking Vascular Pharmacology Beyond the Vessel Wall Modern vascular pharmacology has traditionally focused on smooth muscle cells, endothelial function, and large-scale hemodynamics. Yet a growing body of evidence suggests that one of the most overlooked regulators of vascular tone…

Erectile dysfunction (ED) is often perceived as a localized problem of penile blood flow. In reality, it is frequently a systemic vascular disorder, reflecting deeper disturbances in endothelial function, metabolic health, and inflammatory status. This connection becomes particularly evident in…

Erectile dysfunction (ED) is one of the most common male health conditions worldwide. Over the past two decades, the introduction of phosphodiesterase type-5 (PDE5) inhibitors has dramatically changed its management. Medications such as sildenafil, vardenafil, avanafil, and tadalafil have become…

Pulmonary arterial hypertension (PAH) remains one of the most challenging disorders in cardiovascular medicine. Despite considerable therapeutic progress over the past two decades, the disease continues to carry significant morbidity and mortality. Modern pharmacology has transformed PAH from an almost…

Pulmonary arterial hypertension (PAH) is a progressive and potentially fatal disease characterized by increased pulmonary vascular resistance and remodeling of the pulmonary arteries. Despite major advances in targeted therapies, the management of PAH remains complex and highly individualized. Modern treatment…

Introduction: Why Measuring Erectile Function in Research Still Matters Erectile dysfunction (ED) remains one of the most extensively studied conditions in sexual medicine. Despite the availability of effective pharmacotherapy—including well-known phosphodiesterase type-5 inhibitors such as tadalafil—understanding the mechanisms behind erectile…

Introduction: When Seconds Matter More Than We Admit Premature ejaculation (PE) remains one of the most prevalent male sexual dysfunctions, affecting up to 30% of men under the age of 40. It is defined not merely by speed, but by…

Introduction: When Vision Meets Vasodilation Phosphodiesterase type 5 inhibitors (PDE5 inhibitors) transformed the management of erectile dysfunction (ED). Drugs such as sildenafil, tadalafil, and vardenafil became first-line therapies due to their predictable efficacy, ease of administration, and generally favorable safety…

Introduction: Andropause Is More Than a Hormone Number Modern medicine has grown increasingly comfortable discussing menopause. Andropause, by contrast, still lives in the shadows—frequently dismissed as “just aging” or reduced to a laboratory value on a testosterone report. Yet the…

Pulmonary arterial hypertension (PAH) remains one of the most demanding challenges in modern cardiopulmonary medicine. Despite major therapeutic advances, it continues to carry significant morbidity and mortality. Over the past two decades, targeted therapies have reshaped the disease trajectory, turning…

Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are not forgiving diseases. They are chronic, progressive, and physiologically complex. Over the past two decades, targeted pharmacotherapy has transformed prognosis. Yet even the most elegant pharmacologic strategy fails if…

Modulating Oxidative Stress and Inflammation in Experimental Oncology Introduction: When an Effective Chemotherapeutic Agent Becomes a Double-Edged Sword Doxorubicin remains one of the most potent and widely prescribed anthracycline chemotherapeutic agents in modern oncology. Since its approval in the 1970s,…

The Clinical Problem: Erectile Dysfunction After Prostate Cancer Surgery Radical prostatectomy remains one of the most effective treatments for localized prostate cancer. Advances in surgical technique—particularly bilateral nerve-sparing radical prostatectomy (nsRP)—have dramatically improved functional outcomes. Yet even in the best…

Introduction: A Trusted Drug with an Unexpected Face Tadalafil is widely regarded as a predictable and well-tolerated medication. As a phosphodiesterase-5 (PDE-5) inhibitor, it has earned its place in modern therapeutics for erectile dysfunction, pulmonary arterial hypertension, and benign prostatic…

Introduction: Beyond Classical PDE5 Inhibition Few small molecules have reshaped modern pharmacotherapy as profoundly as tadalafil. Originally developed as a highly selective phosphodiesterase type 5 (PDE5) inhibitor for erectile dysfunction, tadalafil rapidly expanded its clinical relevance to pulmonary arterial hypertension…

The Clinical Intersection of LUTS and BPH: Why the Comparison Matters Lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) remain among the most prevalent and disruptive conditions affecting aging men. Frequency, urgency, nocturia, weak stream, incomplete emptying—these…

Introduction: When Dust Leaves a Vascular Signature Silicosis is often described in the language of fibrosis, nodules, and restrictive physiology. It is a disease of dust inhalation, progressive scarring, and long-term occupational exposure. Yet in some patients, the consequences extend…

Introduction: When Formulation Meets Function Erectile dysfunction (ED) is not a rare inconvenience; it is a global medical condition with profound physiological and psychosocial consequences. Prevalence increases sharply with age, affecting up to 40% of men between 60 and 69…

Introduction: When Prescriptions Tell a National Story Prescription data are more than administrative records; they are epidemiological fingerprints. When analyzed longitudinally, they reveal how a population ages, how clinicians adapt to evolving evidence, and how patients’ expectations shift over time….

Introduction: When Antidepressant Therapy Meets Sexual Physiology Selective serotonin reuptake inhibitors (SSRIs) have transformed psychiatric care. Major depressive disorder, anxiety disorders, obsessive-compulsive disorder, premature ejaculation—these and other conditions are now routinely treated with serotonergic agents. Among them, paroxetine stands out…

Introduction: Erectile Dysfunction Beyond Borders Erectile dysfunction (ED) is often described in epidemiological statistics, biochemical pathways, and therapeutic algorithms. Yet behind every percentage lies a patient, and behind every patient stands a cultural, relational, and psychological framework that shapes both…

Introduction: When Oxygen Falls, So Does Function Erectile dysfunction (ED) is often framed as a vascular disorder of aging, diabetes, or atherosclerosis. Yet an underappreciated contributor lies in sleep physiology—specifically, obstructive sleep apnea (OSA). OSA affects 2–4% of adults and…

Introduction: Two Conditions, One Pathophysiological Thread Benign prostatic growth (BPG), often clinically expressed as benign prostatic hyperplasia (BPH), and erectile dysfunction (ED) are among the most prevalent conditions affecting aging men. Epidemiological data suggest that by the age of 60,…

Introduction: When Urology Intersects with Cardiology Lower urinary tract symptoms (LUTS) are often treated as a localized urological problem—weak stream, urgency, nocturia, incomplete emptying. Yet epidemiological data have repeatedly shown that men with moderate to severe LUTS carry a higher…

Introduction: When the Prostate Meets the Endothelium Benign prostatic hyperplasia (BPH) is usually approached as a local anatomical problem. The prostate enlarges, the urethra narrows, urinary flow weakens, and symptoms accumulate. We prescribe alpha-blockers to relax smooth muscle, 5-alpha reductase…

Introduction: Beyond Erection Hardness — The Psychology of Choice Erectile dysfunction (ED) is often described in vascular terms: impaired nitric oxide signaling, endothelial dysfunction, reduced cavernosal smooth muscle relaxation. These explanations are biologically accurate. Yet they are clinically incomplete. An…

Introduction: When the Bladder and the Penis Share the Same Pathway Lower urinary tract symptoms (LUTS) and erectile dysfunction (ED) are two of the most common and most underestimated conditions affecting aging men. Individually, they reduce quality of life; together,…

Introduction: When Route of Administration Becomes the Clinical Question Erectile dysfunction (ED) management has long been dominated by oral phosphodiesterase type 5 inhibitors (PDE5i). Since the late 1990s, oral sildenafil, tadalafil, vardenafil, and avanafil have transformed sexual medicine. Their efficacy…

Benign prostatic hyperplasia (BPH) rarely arrives alone. It brings obstruction, irritative urinary symptoms, sexual dysfunction, frustration, and — not infrequently — therapeutic disappointment. For many men, especially those previously treated without success, the experience of BPH becomes less about urinary…

Rethinking Erectile Dysfunction Assessment: Beyond Questionnaires Erectile dysfunction (ED) is one of the most common male health conditions worldwide, yet its diagnostic evaluation remains surprisingly subjective. Despite remarkable advances in pharmacotherapy—particularly with phosphodiesterase type 5 inhibitors (PDE5i)—the clinical assessment of…

The Modern Prostatectomy Patient: Cancer Survival Is Not Enough Robot-assisted laparoscopic radical prostatectomy (RALP) has transformed the surgical management of localized prostate cancer. It offers oncological precision, reduced blood loss, shorter hospitalization, and—most importantly for many men—the possibility of nerve…

Understanding the Therapeutic Gap in Diabetes-Related Erectile Dysfunction Erectile dysfunction associated with diabetes mellitus is not merely a variant of classical erectile dysfunction. It is a more resistant, more complex, and often more frustrating clinical entity. Epidemiological data consistently demonstrate…

Pharmacokinetics is often perceived as an abstract discipline confined to curves and clearance values. In reality, it is the quiet architect of clinical safety. When a drug moves through the body, it negotiates with physiology — and physiology changes with…

Introduction: When Metabolism Becomes an Immune Weapon Cancer is often described as a genetic disease, but its most effective weapons are metabolic. Among them, lactic acid has long been viewed as a metabolic byproduct—an inconvenient consequence of aerobic glycolysis. That…

Introduction: When Oral Therapy Reaches Its Ceiling Pulmonary arterial hypertension (PAH) is a disease that rarely forgives therapeutic hesitation. Despite impressive progress in pharmacology over the past two decades, a subset of patients continues to deteriorate even under aggressive combination…

Introduction: When the First Repair Fails Posterior urethral distraction injuries represent one of the most challenging scenarios in reconstructive urology. These injuries, typically associated with severe pelvic trauma, disrupt not only urethral continuity but also the delicate balance of continence,…

Introduction Liver cancer remains one of the most unforgiving malignancies in modern medicine. Despite decades of progress in oncology, hepatocellular carcinoma continues to claim lives with alarming efficiency, particularly in low- and middle-income countries where access to advanced therapies is…

Introduction: Why Another PDE-5 Inhibitor Still Matters Erectile dysfunction (ED) is one of the most common chronic conditions affecting men worldwide, particularly beyond the fourth decade of life. Despite the availability of several well-established phosphodiesterase type 5 (PDE-5) inhibitors, a…

Introduction: When a Tablet Looks Right but Behaves Wrong Counterfeit medicines represent one of the most underestimated threats to modern healthcare. Unlike dramatic medical emergencies, their damage unfolds quietly: through treatment failure, unpredictable adverse effects, erosion of patient trust, and…

Introduction: When Lower Urinary Tract Symptoms Reflect More Than the Prostate Lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) represent one of the most common chronic conditions affecting aging men. While often dismissed as an inevitable consequence…

Introduction: When Vascular Fragility Meets Vascular Remodeling Pulmonary arterial hypertension (PAH) is a relentlessly progressive disease characterized by pulmonary vascular remodeling, elevated pulmonary vascular resistance, and right ventricular failure. Despite advances in targeted therapies, outcomes remain suboptimal in a subset…

Introduction: The Cost of Caution in Pulmonary Arterial Hypertension Pulmonary arterial hypertension (PAH) is a disease in which time is never neutral. Every delay in effective hemodynamic control allows progressive vascular remodeling, irreversible right ventricular strain, and gradual loss of…

Introduction: Erectile Dysfunction as a Vascular Consequence of Dyslipidemia Erectile dysfunction (ED) in middle-aged and elderly men is rarely an isolated disorder. In modern clinical practice, it is increasingly recognized as a vascular manifestation of systemic metabolic disease. Among the…

Introduction: When Two Rare Diseases Collide Pulmonary arterial hypertension (PAH) is a progressive and life-limiting disease defined by pathological remodeling of the pulmonary vasculature, increased pulmonary vascular resistance, and eventual right ventricular failure. Despite advances in targeted therapies, PAH remains…

Introduction: Erectile Dysfunction as a Metabolic Signal, Not a Local Problem Erectile dysfunction (ED) is often misinterpreted as an isolated disorder of sexual performance. In reality, it represents one of the most sensitive clinical indicators of systemic vascular health. The…

Introduction: When Vascular Medicine Meets Real Life The coexistence of erectile dysfunction (ED), benign prostatic hyperplasia (BPH), and arterial hypertension is not a coincidence—it is a predictable consequence of vascular aging. As men grow older, endothelial dysfunction quietly reshapes both…

Introduction: When Similar Molecules Behave Very Differently Pulmonary arterial hypertension (PAH) is a disease defined by precision. Small changes in pulmonary vascular resistance, right ventricular afterload, or oxygenation can translate into large differences in symptoms, functional capacity, and survival. As…

Introduction: When One Mechanism Is No Longer Enough Benign prostatic hyperplasia (BPH) is no longer viewed as a purely anatomical problem of prostate enlargement. It is a chronic, progressive condition characterized by a complex interaction of hormonal, vascular, neuromuscular, and…

Introduction: Lower Urinary Tract Symptoms as a Systemic Problem Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) represent one of the most common chronic conditions affecting aging men. Their prevalence increases steadily with age, and by middle…

Introduction: Solubility as the Quiet Gatekeeper of Oral Therapy In oral drug development, few parameters wield as much influence—and cause as much frustration—as intestinal solubility. A compound may exhibit excellent potency, target selectivity, and metabolic stability, yet fail clinically because…

Introduction: Why Timing May Matter More Than We Thought Erectile dysfunction following radical prostatectomy remains one of the most clinically frustrating and emotionally charged consequences of otherwise successful prostate cancer surgery. Even in the era of nerve-sparing robot-assisted radical prostatectomy…

Introduction: When the Best Therapy Works Only If It Is Taken Pulmonary arterial hypertension (PAH) is a disease that does not forgive inconsistency. Its pathophysiology is relentless, progressive, and largely indifferent to intention. Over the past two decades, the therapeutic…

Introduction: Nitric Oxide Beyond Mammals Nitric oxide (NO) occupies a privileged position in cardiovascular physiology. In mammals, it is almost impossible to discuss vascular tone, endothelial function, or smooth muscle relaxation without invoking the NO–cGMP signaling cascade. Over decades, this…

Introduction: When Manufacturing Parameters Become Therapeutic Variables In modern pharmaceutical technology, the distance between formulation science and clinical outcome is far shorter than it once appeared. A decision made at the level of processing pressure or mechanical conditioning may ultimately…

Radical prostatectomy remains a cornerstone in the management of localized prostate cancer. Advances in surgical technique—particularly nerve-sparing approaches—have transformed oncological outcomes while preserving quality of life. Yet even with meticulous nerve preservation, erectile dysfunction (ED) continues to be one of…

Modern urology increasingly favors minimally invasive solutions. Prostatic artery embolization (PAE) has emerged as an attractive alternative to traditional surgical interventions for benign prostatic hyperplasia (BPH), offering symptom relief without tissue resection and with a lower risk of sexual dysfunction….

Pulmonary arterial hypertension (PAH) has long been described in textbooks as a rare disease of younger patients, often women, with few comorbidities and a clean cardiovascular background. That image is now largely obsolete. Contemporary registries and everyday clinical practice tell…

Erectile dysfunction (ED) is often treated as a local mechanical problem with a systemic medication. That sentence sounds contradictory, but it’s an accurate summary of modern practice. We prescribe phosphodiesterase type 5 inhibitors (PDE5 inhibitors) to improve penile blood flow,…

Lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and erectile dysfunction (ED) are two conditions that like to arrive as a pair—especially as men age. Many patients come in talking about urinary frequency, nocturia, weak stream, or…

Phosphodiesterase type 5 (PDE5) inhibitors—sildenafil, tadalafil, vardenafil, and avanafil—changed erectile dysfunction (ED) care more than any marketing campaign could ever claim. They offered a reliable oral option, moved ED treatment out of the “awkward procedures” category, and gave patients back…

Neurodegeneration is often introduced with a gloomy statistic—and for once, the gloom is justified. Dementia affects tens of millions of people worldwide and is expected to rise dramatically as populations age. In parallel, the therapeutic toolbox for Alzheimer’s disease (AD)…

Erectile function (EF) recovery after bilateral nerve-sparing radical prostatectomy (nsRP) is one of the most emotionally charged “numbers” in modern urology. Not because clinicians enjoy questionnaires, but because patients do. A man can accept a scar, tolerate transient fatigue, and…

Heart failure rarely begins with drama. It begins quietly—an ejection fraction that slips below normal, a ventricle that remodels, a left atrium that enlarges—while the patient still insists they feel “fine.” This stage, commonly called preclinical systolic dysfunction (PSD) and…

Erectile dysfunction (ED) drugs are often discussed in the language of convenience: “quick onset,” “long duration,” “works when you need it.” That framing is practical, but biologically incomplete. Phosphodiesterase type 5 (PDE5) inhibitors do not operate only in the penis;…

Radical prostatectomy remains one of the most effective curative options for localized prostate cancer. The surgery is technically elegant, oncologically meaningful, and—if you ask most patients—life-saving. Then the postoperative reality arrives with less elegance: erectile dysfunction (ED) and urinary incontinence…

Erectile dysfunction (ED) is often described in textbooks with neat definitions, but in real clinics it behaves like a chronic condition with mood swings. A patient may do “fine” for months, then relapse after stress, vascular progression, or simply aging…

Introduction: Oral Drug Absorption Begins with Dissolution, Not with Hope Oral administration remains the dominant route for drug delivery, not because it is perfect, but because patients tolerate it and regulators understand it. Yet, from a biopharmaceutical perspective, swallowing a…

Introduction: Erectile Dysfunction as a Multisystem Disorder, Not a Local Accident Erectile dysfunction (ED) is often introduced in textbooks as a mechanical failure of penile blood flow, but in real clinical practice it behaves more like a systemic barometer. It…

Introduction: Why Reperfusion Injury Remains the Achilles’ Heel of Lung Transplantation Despite remarkable advances in surgical technique, donor management, and perioperative care, lung transplantation continues to be burdened by a complication as old as the procedure itself: ischemia–reperfusion injury. Clinically,…

Introduction: Why Drug Interactions Matter More Than Ever in PAH Pulmonary arterial hypertension (PAH) has evolved dramatically over the past three decades. Once a rapidly fatal disease with limited therapeutic options, it is now a chronic condition managed through sophisticated,…

Introduction: Erectile Dysfunction as a Silent Burden of Chronic Renal Failure Chronic renal failure (CRF) is no longer viewed solely as a disorder of impaired filtration and metabolic imbalance. Modern clinical practice increasingly recognizes CRF as a systemic disease with…

Introduction: Erectile Dysfunction Beyond Sexual Performance Erectile dysfunction (ED) has long ceased to be viewed merely as a disorder of sexual performance. In modern clinical medicine, ED is increasingly recognized as a sentinel marker of systemic vascular pathology, often preceding…

Introduction: Drug-Induced PAH Is Rare—Until It Is Not Pulmonary arterial hypertension (PAH) is often taught as a disease of idiopathic mutations, connective tissue disorders, or congenital heart disease. In daily practice, however, clinicians increasingly encounter PAH as an iatrogenic condition,…